CD2 and neoplasm: A study revealed that CD2 deficiency downregulates the anti-tumor capacity of CAR-T cells in a xenograft mouse model, whereas treatment with exogenous interleukins could effectively reverse the anti-tumor effector capacity of immune cells, which supports the adjuvant therapeutic role of T-cell factor release in T-ALL [12].